Ph2 study evaluating the efficacy of Lymphotic Leukemia with covalent bruton tyrosine kinase
Phase II Clinical Trial
A Phase 2 Open-Label Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor (J2N-MC-JZNX)
Participating Locations